<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00386126</url>
  </required_header>
  <id_info>
    <org_study_id>HCPA 06-115</org_study_id>
    <nct_id>NCT00386126</nct_id>
  </id_info>
  <brief_title>Iron Supplementation in Heart Failure Patients With Anemia: The IRON-HF Study</brief_title>
  <official_title>Randomized Trial to Assess the Effects of Iron Supplementation in Heart Failure Patients With Anemia: The IRON-HF Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <brief_summary>
    <textblock>
      Anemia has been demonstrated to be a common finding in patients with heart failure (HF).&#xD;
      Previous studies in hospitalized patients with HF have found a prevalence of anemia ranging&#xD;
      from 15% to 63%. More importantly, anemic patients with HF have increased morbidity and&#xD;
      mortality. The mechanisms underlying anemia in HF are multifactorial, involving mild to&#xD;
      moderate forms of anemia of chronic disease and ferropenic anemia. The clinical impact of&#xD;
      iron supplementation in HF patients who have a relatively preserved renal function and either&#xD;
      chronic disease anemia, ferropenic anemia or both remains largely unknown. The route of iron&#xD;
      administration that could be most clinically effective is also unclear. Thus, the primary aim&#xD;
      of the IRON-HF study is to assess the effects of iron supplementation alone (IV or PO) on&#xD;
      parameters of functional capacity in HF patients with anemia with decreased availability of&#xD;
      iron.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The IRON-HF study is an investigator initiated, multicenter, prospectively&#xD;
      designed,randomized, double-blind, placebo controlled clinical trial.&#xD;
&#xD;
      Randomization:Each of the eight participating centers will randomize patients by telephone&#xD;
      contact with the randomization center at Hospital de Clínicas de Porto Alegre. The&#xD;
      randomization system will be based on a computerized table of random numbers and performed in&#xD;
      blocks of three per participating center.&#xD;
&#xD;
      Blinding:Each participating center will elect a third party blind individual (usually a RN)&#xD;
      who will open the allocated medication box, prepare iron sucrose infusions or saline and&#xD;
      administer to patients in opaque devices. Both patient and attending physicians and/or nurses&#xD;
      will be blind to allocated therapy. Oral medications and oral placebo will be identical in&#xD;
      all aspects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2006</start_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of the IRON-HF study is to assess the impact of iron supplementation alone (IV or PO) on changes in oxygen maximal consumption (peak VO2) assessed by ergospirometry over a 3-month follow-up period.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) functional class</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BNP (B-type natriuretic peptide) levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using the Living with Heart Failure Minnesota Questionnaire</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction (LVEF) as assessed by the bi-planar modified Simpson method in two-dimensional echocardiography</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function as assessed by the serum levels of creatinine</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hospitalizations due to HF</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (drug tolerance).</measure>
  </secondary_outcome>
  <enrollment>117</enrollment>
  <condition>Heart Failure</condition>
  <condition>Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Sucrose IV 200mg, once a week, for 5 weeks</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous sulfate 200mg PO TID, for 8 weeks</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older;&#xD;
&#xD;
          -  Outpatients followed at a HF Clinic in a tertiary care Hospital with clinical&#xD;
             diagnosis of HF for at least 3 months before study entry;&#xD;
&#xD;
          -  NYHA functional class II to IV, who are able to perform ergospirometry;&#xD;
&#xD;
          -  Documentation of LVEF &lt; 40% within the last 6 months;&#xD;
&#xD;
          -  Adequate baseline therapy for HF based on patient's functional class (β-blockers, ACE&#xD;
             inhibitors irrespective of functional class except if contra-indications, digoxin,&#xD;
             spironolactone if NYHA class III or IV);&#xD;
&#xD;
          -  Stable baseline HF therapy with same doses of medications and no intent to increase&#xD;
             doses for the following 3 months;&#xD;
&#xD;
          -  Hemoglobin ≤ 12 g/dl and &gt; 9 g/dl;&#xD;
&#xD;
          -  Transferrin saturation &lt; 20% and ferritin &lt; 500 µg/L;&#xD;
&#xD;
          -  Ability to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically overt bleeding: gastrointestinal bleeding, hypermenorrhea, history of&#xD;
             peptic ulcer without evidence of healing or inflammatory intestinal diseases;&#xD;
&#xD;
          -  Uncorrected hypothyroidism;&#xD;
&#xD;
          -  Other inflammatory, neoplastic or infectious disease;&#xD;
&#xD;
          -  Serum creatinine &gt; 1,5 mg/dl;&#xD;
&#xD;
          -  Previous intolerance to oral elemental iron compounds;&#xD;
&#xD;
          -  HF due to alcoholic cardiomyopathy, current regular drinker of alcoholic beverages or&#xD;
             HF due to peripartum cardiomyopathy;&#xD;
&#xD;
          -  Recent admission for decompensated HF (last month)&#xD;
&#xD;
          -  Recent myocardial revascularization procedures (last 3 months);&#xD;
&#xD;
          -  Recent ACS, stroke or TIA (last 3 months);&#xD;
&#xD;
          -  Active or metastatic neoplastic disease with life expectancy of less than a year;&#xD;
&#xD;
          -  Patients in heart transplantation list;&#xD;
&#xD;
          -  Patients that had participated in any other clinical trial or study within the last&#xD;
             month;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Pre-menopausal women that are not using any effective method of contraception;&#xD;
&#xD;
          -  Patients using prohibited medications or that have not yet accomplished the wash-out&#xD;
             period;&#xD;
&#xD;
          -  Patients currently participating in cardiovascular rehabilitation programs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadine Clausell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luis Beck-da-Silva, MD</last_name>
    <phone>55 51 21018657</phone>
    <phone_ext>8657</phone_ext>
    <email>lbneto@hcpa.ufrgs.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle C Assis, RN</last_name>
    <phone>55 51 21018657</phone>
    <phone_ext>8657</phone_ext>
    <email>mcassis@hcpa.ufrgs.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular Division, Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Beck-da-Silva, MD</last_name>
      <phone>55 5121018344</phone>
      <phone_ext>8344</phone_ext>
      <email>lbneto@hcpa.ufrgs.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2006</verification_date>
  <study_first_submitted>October 6, 2006</study_first_submitted>
  <study_first_submitted_qc>October 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2006</study_first_posted>
  <last_update_submitted>October 6, 2006</last_update_submitted>
  <last_update_submitted_qc>October 6, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2006</last_update_posted>
  <keyword>Heart Failure</keyword>
  <keyword>Anemia</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Oxide, Saccharated</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

